Handelsbanken Fonder Ab Crinetics Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 19,000 shares of CRNX stock, worth $744,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,000
Previous 16,400
15.85%
Holding current value
$744,800
Previous $735,000
32.11%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$246 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$244 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$231 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$194 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$175 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.11B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...